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The National Institute of Science and Technology in
Oncogenomics (INCT) established a scientific program
that links 46 researchers and supports their efforts to
translate research findings into clinical practice, including
clinical trials. Our initiative focused in the management of
resources of three areas: research networks; chair pro-
grams and infrastructure support; transference of new
knowledge, which can reduce the burden of cancer,
quickly and efficiently to the Brazilian healthcare system.
The National Institute of Science and Technology in
Oncogenomics was created by the Brazilian Ministry of
Science and Technology in search of excellence in scienti-
fic activities at an international level, by means of pro-
grams and instruments made operationally by CNPq
(National Council for Scientific and Technological Devel-
opment) and FAPESP (São Paulo Research Foundation).
The major aim of this study is recruit cancer patients
from families with a history of family aggregation or her-
editary cancer and relatives, affected or not, in order to
obtain molecular and epidemiological data. We are investi-
gating genomic alterations in the probands and in their
relatives, including at least one who is a cancer carrier
(not necessarily the same tumor type). Genomes vary from
one another in several ways and the totality of this genetic
variation is the basis of human traits heritability. Genome
re-sequencing studies have shown that the bases that vary
among genomes reside in CNVs (Copy Number Varia-
tions) ranging in size from kilobases (kb) to megabases
(Mb), which are not identifiable by conventional chromo-
somal banding. Deletions, duplications, amplifications,
insertions, and translocations can result in CNVs. In addi-
tion, balanced genomic inversions leading to DNA struc-
tural variations that do not cause CNV can nevertheless
contribute significantly to genome instability. Despite
extensive studies, the total number, position, size, gene
content, and population distribution of CNVs remain elu-
sive. Although it is estimated that CNVs may account in a
large proportion of the human genome, the association
between CNVs and human cancer is limited. It is antici-
pated that the application of array CGH techniques and
next-generation sequencing will reveal a significantly lar-
ger scale of structural variation among different indivi-
duals and populations, as the majority of CNVs appear
smaller in scale and are beyond the resolving capability of
current arrays [1,2]. CNVs can be inherited or sporadic;
large de novo CNVs are thought more likely to be disease
causative. However, the phenotypic effects of CNVs are
sometimes unclear and depend mainly on whether
dosage-sensitive genes or regulatory sequences are affected
by the genomic rearrangement. Sporadic disease can also
result from a combination of two CNVs at a single locus
or theoretically from two or more CNVs at different loci
from two normal parents [3].
Despite the fact that cancer is an acquired disease
caused by various factors, there is clear evidence that
inherited factors play a significant role. Some of these
inherited factors represent loss-of-function mutations in
tumor suppressor genes, resulting in a high relative cancer
risk among carriers. In particular, rare constitutional
CNVs may affect important cancer-associated genes or
pathways, providing an explanation for high-risk cancer
families. The first approach of this study is to investigate
clinically and genetically the most common cancers asso-
ciated with hereditary predisposition (breast, ovary, color-
ectal, head and neck carcinomas) in a Brazilian Network
of Cancer involving Reference Health Care Cancer
Centers.
It is accepted that 5 to 10% of all cancers are hereditary
or familial [4]. The majority of hereditary neoplasias
related to breast cancer are associated with germline
mutations in BRCA1 and BRCA2. However, inherited
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mutations related to other genes and/or related to certain
syndromes also influence the increased risk of developing
cancer. Li-Fraumeni syndrome results in a mutation on
gene TP53 and is related to increased risk of developing
tumors at a young age. A deletion in gene CHEK2 is
associated with a two-fold greater risk of the patient pre-
senting breast cancer. Hereditary nonpolyposis colorectal
cancer (HNPCC) associated with mutation in the DNA
damage repair genes, such as MLH1 and MSH2, constitu-
tes a risk factor for the development of extracolonic
tumors, including breast tumors [5].
The possibility of identifying a Brazilian profile of the
syndrome has permitted our group to propose new tracing
strategies aimed at contributing to early detection of dis-
ease carriers among Brazilians. The Department of Onco-
genetics of the AC Camargo Hospital was created in 2000
and since then, more than 4,500 patients and family mem-
bers have received Genetic Counseling. The Oncotree
software is used to monitor family history data. In the AC
Carmago Hospital peripheral blood DNA samples of
patients with hereditary cancer or family history or familial
aggregation of cancer have been recruited over the years.
Some of these families were selected because they pre-
sented all but one of the international criteria adopted in
the categorization of a Familial Cancer Syndrome. In this
project, affected family members (with screening of patho-
genic mutations in the major candidate genes) are under
evaluation by array-CGH and next generation sequencing.
The objective is to publicize rare genomic alterations that
could contain new hereditary predisposition genes, aimed
at defining or identifying new markers of risk of suscept-
ibility to cancer. Here, we discuss the new findings in pro-
bands without mutations in genes frequently described as
associated with the breast and ovary syndrome, Lynch syn-
drome, breast and colorectal syndrome as well as future
perspectives of application of these results.
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